Worth reading
55In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Decision and Details
Development status and future plans for the anti-HIV antibody for which a patent application has been filed
ImplementationPlans to begin establishing a master cell bank for antibody-producing cells during the current fiscal year, and to begin manufacturing the investigational drug and submit a clinical trial notification to the PMDA during the 46th fiscal year
Going forwardThe company plans to begin establishing a master cell bank for antibody-producing cells during the current fiscal year, and to begin manufacturing the investigational drug and submit a clinical trial notification to the PMDA during the 46th fiscal year. If any matters requiring disclosure arise in the future, the company will promptly notify the public.
Quantity / scaleA 4-week repeated-dose toxicity study and a 4-week recovery study using monkeys
Reason
CURED is advancing development with support from AMED, and the nonclinical toxicity study has encountered no issues to date and is progressing smoothly in all respects
Impact on Business Performance
No impact on the company's consolidated financial results for the fiscal year ending March 2027 is expected
| Item | Details |
|---|---|
| Matter Covered | Development status and future plans for the anti-HIV antibody for which a patent application has been filed |
| Implementation Date | Plans to begin establishing a master cell bank for antibody-producing cells during the current fiscal year, and to begin manufacturing the investigational drug and submit a clinical trial notification to the PMDA during the 46th fiscal year |
| Quantity / scale | A 4-week repeated-dose toxicity study and a 4-week recovery study using monkeys |
| Impact on Business Performance | No impact on the company's consolidated financial results for the fiscal year ending March 2027 is expected |
| Reason | CURED is advancing development with support from AMED, and the nonclinical toxicity study has encountered no issues to date and is progressing smoothly in all respects |
| Future plans | The company plans to begin establishing a master cell bank for antibody-producing cells during the current fiscal year, and to begin manufacturing the investigational drug and submit a clinical trial notification to the PMDA during the 46th fiscal year. If any matters requiring disclosure arise in the future, the company will promptly notify the public. |
Items this document does not state (6)
Decision-Making BodyDecision DatePeriod CoveredAmountGoverning RuleRelated previous disclosures
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.CURED is advancing development with support from AMED. It explained that the nonclinical toxicity study has encountered no issues to date and is progressing smoothly in all respects.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.